Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4549-4549 ◽  
Author(s):  
S. Han ◽  
S. R. Park ◽  
K. Lee ◽  
H. Song ◽  
M. A. Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
First Line ◽  
Biomarker Analysis ◽  
First Line Treatment

scholarly journals Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

2019 ◽  
Vol 84 (6) ◽  
pp. 1365-1365
Author(s):  
Fernando Rivera ◽  
C. Romero ◽  
P. Jimenez-Fonseca ◽  
M. Izquierdo-Manuel ◽  
A. Salud ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
First Line Treatment

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine.

Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4033-4033 ◽  
Author(s):  
Peter C. Thuss-Patience ◽  
Salah-Eddin Al-Batran ◽  
Jens T Siveke ◽  
Nils Homann ◽  
Peter Malfertheiner ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Randomized Phase Ii ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document